390 related articles for article (PubMed ID: 19908924)
21. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.
Graham J; Mauskopf J; Kawai K; Johnson KD; Xu R; Acosta CJ
J Manag Care Spec Pharm; 2016 Jul; 22(7):872-88. PubMed ID: 27348287
[TBL] [Abstract][Full Text] [Related]
22. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
[TBL] [Abstract][Full Text] [Related]
26. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
Van Oorschot D; Anastassopoulou A; Poulsen Nautrup B; Varghese L; von Krempelhuber A; Neine M; Lorenc S; Curran D
Hum Vaccin Immunother; 2019; 15(1):34-44. PubMed ID: 30130448
[TBL] [Abstract][Full Text] [Related]
28. Sponsorship Bias in Base-Case Values and Uncertainty Bounds of Health Economic Evaluations? A Systematic Review of Herpes Zoster Vaccination.
Bilcke J; Verelst F; Beutels P
Med Decis Making; 2018 Aug; 38(6):730-745. PubMed ID: 29799803
[TBL] [Abstract][Full Text] [Related]
29. The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older.
Lopez-Belmonte JL; Cisterna R; Gil de Miguel A; Guilmet C; Bianic F; Uhart M
J Med Econ; 2016 Jun; 19(6):576-86. PubMed ID: 26808422
[TBL] [Abstract][Full Text] [Related]
30. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.
Bresse X; Annemans L; Préaud E; Bloch K; Duru G; Gauthier A
Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):393-406. PubMed ID: 23537397
[TBL] [Abstract][Full Text] [Related]
31. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
Johnson RW
Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
[TBL] [Abstract][Full Text] [Related]
32. COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.
Coretti S; Codella P; Romano F; Ruggeri M; Cicchetti A
Int J Technol Assess Health Care; 2016 Jan; 32(4):233-240. PubMed ID: 27624398
[TBL] [Abstract][Full Text] [Related]
33. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S
Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285
[TBL] [Abstract][Full Text] [Related]
34. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
Oh H; Tan C; Williams C; Giannelos N; Ng C
Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Köster I; Reinhold T; Siedler A; Krause G; Icks A; Schubert I; Wichmann O
Eur J Health Econ; 2013 Dec; 14(6):1015-26. PubMed ID: 23271349
[TBL] [Abstract][Full Text] [Related]
37. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
Singer D; Salem A; Stempniewicz N; Ma S; Poston S; Curran D
Vaccine; 2023 Aug; 41(37):5360-5367. PubMed ID: 37541822
[TBL] [Abstract][Full Text] [Related]
38. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV
Eriksson J; Hunger M; Bourhis F; Thorén R; Popmihajlov Z; Finelli L; Jiang Y
Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):613-621. PubMed ID: 31721601
[No Abstract] [Full Text] [Related]
39. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
[TBL] [Abstract][Full Text] [Related]
40. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H
Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
